{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T06:42:28Z","timestamp":1769755348874,"version":"3.49.0"},"reference-count":29,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University Hospitals in Limoges and Poitiers"},{"name":"CEID in Bordeaux"},{"DOI":"10.13039\/501100017007","name":"Regional Health Agency","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100017007","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The SCANVIR\u00ae project is a regional initiative aimed at accelerating the elimination of hepatitis C virus (HCV) by reaching high-risk populations outside traditional healthcare settings. Launched in 2017 in Limoges and later expanded to Poitiers and Bordeaux, the project organized dedicated screening and treatment days in 43 facilities taking care of intravenous drug users, migrants, and prisoners in Nouvelle-Aquitaine. These events involved multidisciplinary teams and advanced diagnostic tools, including rapid tests for HCV, HBV, and HIV; FibroScan\u00ae for liver assessment; and GeneXpert\u00ae for on-site HCV RNA detection. Patients also received counseling on risk prevention, addiction, psychosocial support, and treatment when needed. Between 2017 and 2024, SCANVIR\u00ae screened 1664 patients, with 98.9% accepting FibroScan\u00ae. Anti-HCV antibodies were detected in 23.4% of participants, among whom 41.5% (N = 162) had a replicative profile. Of these, 83% initiated treatment and 80% were cured or were still undergoing therapy. FibroScan\u00ae assessments showed advanced fibrosis in 17% of patients, severe fibrosis in 7.2%, and severe steatosis in 18%. By promoting a \u201cTest, Treat, Prevent\u201d strategy, SCANVIR\u00ae proved cost-effective in diagnosing and treating individuals distant from care structures, highlighting the value of integrating education and prevention into liver disease screening. SCANVIR\u00ae is an officially registered European trademark.<\/jats:p>","DOI":"10.3390\/v18020151","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T10:41:34Z","timestamp":1769164894000},"page":"151","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The SCANVIR\u00ae Project: A Success in Hepatitis C Micro-Elimination in Nouvelle-Aquitaine"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7670-8115","authenticated-orcid":false,"given":"Sandrine","family":"Francois","sequence":"first","affiliation":[{"name":"Hepato-Gastroenterology Department, University Hospital Center, 87042 Limoges, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gwennaick","family":"Villain","sequence":"additional","affiliation":[{"name":"Hepato-Gastroenterology Unit, University Hospital Center, 86000 Poitiers, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samy","family":"Yahiaoui","sequence":"additional","affiliation":[{"name":"Risk-Reduction Centers for Drug Users (CAARUD Planterose), Committee for Study and Information on Drugs and Addictions (CEID), 33000 Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0712-8491","authenticated-orcid":false,"given":"Christine","family":"Silvain","sequence":"additional","affiliation":[{"name":"Hepato-Gastroenterology Unit, University Hospital Center, 86000 Poitiers, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Reiller","sequence":"additional","affiliation":[{"name":"Risk-Reduction Centers for Drug Users (CAARUD Planterose), Committee for Study and Information on Drugs and Addictions (CEID), 33000 Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9750-2506","authenticated-orcid":false,"given":"Paul","family":"Carrier","sequence":"additional","affiliation":[{"name":"Hepato-Gastroenterology Department, University Hospital Center, 87042 Limoges, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9787-1421","authenticated-orcid":false,"given":"Sophie","family":"Alain","sequence":"additional","affiliation":[{"name":"Virology Department, University Hospital Center, 87042 Limoges, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronique","family":"Loustaud-Ratti","sequence":"additional","affiliation":[{"name":"Hepato-Gastroenterology Department, University Hospital Center, 87042 Limoges, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilyne","family":"Debette-Gratien","sequence":"additional","affiliation":[{"name":"Hepato-Gastroenterology Department, University Hospital Center, 87042 Limoges, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"102255","DOI":"10.1016\/j.tmaid.2022.102255","article-title":"Global Prevalence of Hepatitis C in General Population: A Systematic Review and Meta-Analysis","volume":"46","author":"Salari","year":"2022","journal-title":"Travel Med. Infect. Dis."},{"key":"ref_2","unstructured":"World Health Organization (2022). Global Health Sector Strategies on, Respectively, HIV, Viral Hepatitis and Sexually Transmitted Infections for the Period 2022\u20132030, World Health Organization."},{"key":"ref_3","unstructured":"World Health Organization (2024). Priorities in Planning Person-Centred Hepatitis B and C Testing Services: Operational Guide, World Health Organization."},{"key":"ref_4","unstructured":"Brouard, C. (2023). D\u00e9pistage des H\u00e9patites B et C en 2021 en France, Enqu\u00eate LaboHEP\/Hepatites B and C Testing in 2021 in France, LaboHEP Survey. Bull \u00c9pid\u00e9miol Hebd., 276\u2013286. Available online: http:\/\/beh.santepubliquefrance.fr\/beh\/2023\/15-16\/2023_15-16_1.html."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/liv.14779","article-title":"Progress towards Hepatitis C Virus Elimination in High-Income Countries: An Updated Analysis","volume":"41","author":"Gamkrelidze","year":"2021","journal-title":"Liver Int."},{"key":"ref_6","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 Fiche M\u00e9mo (2023). H\u00e9patite C: Prise en Charge Simplifi\u00e9e Chez L\u2019Adulte, Haute Autorit\u00e9 de Sant\u00e9."},{"key":"ref_7","unstructured":"Minist\u00e8re Des Affaires Sociales ET de la Sant\u00e9 (2023). Conditions de R\u00e9alisation des Tests Rapides D\u2019Orientation Diagnostique de L\u2019Infection par Les Virus de L\u2019Immunod\u00e9ficience Humaine (Vih 1 ET 2) ET de L\u2019Infection par Le Virus de L\u2019H\u00e9patite C (VHC) en Milieu M\u00e9dico-Social Ou Associatif."},{"key":"ref_8","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 (2023). Evaluation des Strat\u00e9gies de D\u00e9pistage des Personnes Infect\u00e9es par Le Virus de L\u2019H\u00e9patite C, Haute Autorit\u00e9 de Sant\u00e9."},{"key":"ref_9","first-page":"445","article-title":"Pr\u00e9valence de l\u2019infection Par Le VIH et Le Virus de l\u2019h\u00e9patite C Chez Les Personnes D\u00e9tenues En France. R\u00e9sultats de l\u2019enqu\u00eate Pr\u00e9vacar 2010","volume":"35","author":"Chiron","year":"2013","journal-title":"Bull. Epid\u00e9miol. Hebd."},{"key":"ref_10","first-page":"188","article-title":"D\u00e9pistage des h\u00e9patites B et C en France en 2016, nouvelle \u00e9dition de l\u2019enqu\u00eate LaboHep\/Hepatitis B and C Screening in France in 2016","volume":"11","author":"Pioche","year":"2018","journal-title":"Bull. Epid\u00e9miol. Hebd."},{"key":"ref_11","first-page":"S27","article-title":"\u00c9tude de La Pr\u00e9valence de l\u2019infection \u00e0 VIH et Des H\u00e9patites B et C, et Chez Les Migrants R\u00e9guliers En France: Donn\u00e9es de l\u2019\u00e9tude STRADA (2017\u20132020)","volume":"1","author":"Duracinsky","year":"2022","journal-title":"M\u00e9decine Mal. Infect. Form."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/jvh.13798","article-title":"Towards Hepatitis C Elimination in France: Scanvir, an Effective Model to Test and Treat Drug Users on Dedicated Days","volume":"30","author":"Chevalier","year":"2023","journal-title":"J. Viral Hepat."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","volume":"81","author":"Tacke","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/flgastro-2021-102064","article-title":"EASL Clinical Practice Guidelines: Non-Invasive Liver Tests for Evaluation of Liver Disease Severity and Prognosis","volume":"13","author":"Archer","year":"2022","journal-title":"Frontline Gastroenterol."},{"key":"ref_15","unstructured":"Alain, S., Lafarge, M., Avez, D., Hanz, S., Loustaud-Ratti, V., Debette-Gratien, M., and Fran\u00e7ois, S. (2024, January 16\u201317). A HCV GeneXpert\u00ae Usage Review: The SCANVIR Project Experience. Proceedings of the 44\u00e8me R\u00e9union Interdisciplinaire de Chimioth\u00e9rapie Anti-Infectieuse, Paris, France."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Mazumder, H., Hossain, M.F., Shrestha, P., Mahmud, S., Husain, M., and Ahmed, R. (2024). Prevalence and Associated Risk Factors of Current Hepatitis C Infection among U.S. General Population and Injection Drug Users Aged 20\u201359 Years: NHANES 2009\u20132018. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0309345"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Avramovic, G., O\u2019Doherty, L., McHugh, T., Remy, A.J., Happiette, A., Bouchkira, H., Murat, P., Scemama, O., Esclade, A., and Farfan Camacho, M.I. (2024). Benchmarking of an Intervention Aiming at the Micro-Elimination of Hepatitis C in Vulnerable Populations in Perpignan, France, to Inform Scale-Up and Elimination on the French Territory. Viruses, 16.","DOI":"10.3390\/v16101645"},{"key":"ref_18","first-page":"337","article-title":"D\u00e9pistage des H\u00e9patites Virales et du vih Dans les Structures M\u00e9dico-Sociales D\u2019addictologie (Csapa et Caarud), France, 2018\u20132023","volume":"2024","author":"Chevaliez","year":"2024","journal-title":"Bull. \u00c9pid\u00e9miol. Hebd."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.jhep.2018.05.027","article-title":"Assessing the Cost-Effectiveness of Hepatitis C Screening Strategies in France","volume":"69","author":"Huneau","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.cgh.2018.08.080","article-title":"Cost Effectiveness of Universal Screening for Hepatitis C Virus Infection in the Era of Direct-Acting, Pangenotypic Treatment Regimens","volume":"17","author":"Eckman","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_21","unstructured":"Barbot, F. (2022). DEPICRA: Une Etude Sur Les Facteurs Influen\u00e7ant L\u2019acc\u00e8s au D\u00e9pistage du VIH et des H\u00e9patites B et C chez les Patients dans les Centres de R\u00e9tention Administrative Fran\u00e7ais. Analyse Qualitative Th\u00e9matique avec Entretiens Individuels Semi-Dirig\u00e9s et Focus Group. M\u00e9decine Hum. Pathol., 396. Available online: https:\/\/dumas.ccsd.cnrs.fr\/dumas-03775564."},{"key":"ref_22","unstructured":"(2025, December 02). LOI N\u00b0 2016-41 Du 26 Janvier 2016 de Modernisation de Notre Syst\u00e8me de Sant\u00e9. JORF n\u00b0 0022 du 27 Janvier 2016. Available online: https:\/\/www.legifrance.gouv.fr\/jorf\/id\/JORFTEXT000031912641\/."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"33028","DOI":"10.1038\/s41598-025-18733-0","article-title":"Screening of Advanced Fibrosis and Metabolic Dysfunction-Associated Steatotic Liver Disease Using Transient Elastography in Vulnerable Population","volume":"15","author":"Nastasa","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/add.14012","article-title":"Needle and Syringe Programmes and Opioid Substitution Therapy for Preventing HCV Transmission among People Who Inject Drugs: Findings from a Cochrane Review and Meta-Analysis","volume":"113","author":"Platt","year":"2018","journal-title":"Addiction"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12954-021-00506-3","article-title":"The State of Harm Reduction in Prisons in 30 European Countries with a Focus on People Who Inject Drugs and Infectious Diseases","volume":"18","author":"Montanari","year":"2021","journal-title":"Harm Reduct. J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"22m14623","DOI":"10.4088\/JCP.22m14623","article-title":"Evaluation of Hepatitis C Screening and Treatment Among Psychiatry Inpatients","volume":"84","author":"Mandel","year":"2023","journal-title":"J. Clin. Psychiatry"},{"key":"ref_27","unstructured":"(2025, December 02). Projet R\u00e9gional de Sant\u00e9 Nouvelle Aquitaine 2018\u20132023, Available online: https:\/\/www.nouvelle-aquitaine.ars.sante.fr\/le-projet-regional-de-sante-nouvelle-aquitaine-2018-2028-0."},{"key":"ref_28","first-page":"11","article-title":"The HCV Sicily Network: A Web-Based Model for the Management of HCV Chronic Liver Diseases","volume":"20","author":"Cartabellotta","year":"2016","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/cld.1180","article-title":"Eliminating Hepatitis C in Mexico: A Primary Health Care Approach","volume":"18","author":"Kershenobich","year":"2021","journal-title":"Clin. Liver Dis."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/2\/151\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T05:11:24Z","timestamp":1769317884000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/2\/151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["v18020151"],"URL":"https:\/\/doi.org\/10.3390\/v18020151","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]}}}